Pulmonary sarcomatoid_MEDI4736+Treme
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
DRUG: durvalumab + tremelimumab
Response rate (RR), According to modified RECIST1.1, The duration from the first date of treatment to the date of death from any cause or follow-up, 12 months after the first date of treatment
Progression-Free Survival (PFS), The percentage of patients who have not experienced disease progression or death from any cause within 12 months from the start of treatment., 12 months after the first date of treatment|Overall Survival (OS), The duration from the first date of treatment to the date of death from any cause or follow-up, 12 months after the first date of treatment|Safety, The number of patients with treatment-related AE as assessed by NCI CTCAE version 4.0, 12 months after the first date of treatment
This is a phase II multi-center, open-label study to evaluate efficacy and safety of durvalumab + tremelimumab combination treatment in patients with pulmonary sarcomatoid carcinoma